Abstract
Endometriosis can recur after either surgical or medical therapy. Long-term medical therapy is implemented to treat symptoms or prevent recurrence. Dienogest and gonadotropin-releasing hormone (GnRH) analogues with hormone add-back therapy seem to be equally effective for long-term treatment of pain symptoms associated with endometriosis. There is insufficient evidence to support the superiority of one therapy over the other. However, add-back hormone therapy (HT) is recommended for patients using GnRH agonists. The treatment selection depends on therapeutic effectiveness, tolerability, drug cost, the physician's experience, and expected patient compliance.
Keywords:
Dienogest; GnRH-a; endometriosis; hormone add-back; long term.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Adolescent
-
Adult
-
Age Factors
-
Contraceptives, Oral, Combined / administration & dosage*
-
Contraceptives, Oral, Combined / adverse effects
-
Contraceptives, Oral, Combined / economics
-
Cost-Benefit Analysis
-
Drug Costs
-
Drug Therapy, Combination
-
Endometriosis / diagnosis
-
Endometriosis / drug therapy*
-
Endometriosis / economics
-
Endometriosis / physiopathology
-
Endometrium / drug effects*
-
Endometrium / pathology
-
Endometrium / physiopathology
-
Female
-
Gonadotropin-Releasing Hormone / agonists*
-
Humans
-
Medication Adherence
-
Nandrolone / administration & dosage
-
Nandrolone / adverse effects
-
Nandrolone / analogs & derivatives*
-
Nandrolone / economics
-
Pelvic Pain / diagnosis
-
Pelvic Pain / drug therapy*
-
Pelvic Pain / economics
-
Pelvic Pain / physiopathology
-
Progestins / administration & dosage*
-
Progestins / adverse effects
-
Progestins / economics
-
Recurrence
-
Treatment Outcome
-
Young Adult
Substances
-
Contraceptives, Oral, Combined
-
Progestins
-
Gonadotropin-Releasing Hormone
-
dienogest
-
Nandrolone